Should we use β-blockers for myocardial infarction?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 11, 2014, Pages 569-572

  Duceppe, Emmanuelle ^a,b   Devereaux, P J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; EDITORIAL; FATIGUE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; SYSTEMATIC REVIEW (TOPIC); MYOCARDIAL INFARCTION;

ADRENERGIC BETA-ANTAGONISTS; HUMANS; MYOCARDIAL INFARCTION;

EID: 84916882890     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2487     Document Type: Editorial

References (20)

1. Che Q, Schreiber MJ, Rafey MA. Beta-blockers for hypertension: are they going out of style? Cleve Clin J Med. 2009; 76: 533-542.
2. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers - a critical review of the evidence. J Am Coll Cardiol. 2007; 50: 563-572.
3. Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012; 11: CD002003.
4. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311: 507-520.
5. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2014; 30: 485-501.
6. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008; 371: 1839-1847.
7. Bouri S, Shun-Shin MJ, Cole GD, et al. Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery. Heart. 2014; 100: 456-464.
8. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127: e362-e425.
9. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33: 2569-2619.
10. Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124: 2458-2473.
11. Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ. 2012; 344: d8059.
12. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986; 2: 57-66.
13. Chen ZM, Pan HC, Chen YP, et al. COMMIT (CIOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366: 1622-1632.
14. Edwards J, Goodman SG, Yan RT, et al. Has the CIOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2011; 161: 291-297.
15. Bangalore S, Makani H, Radford M, et al. Clinical Outcomes with β-blockers for myocardial infarction a meta-analysis of randomized trials. Am J Med. 2014; 127: 939-953.
16. Rasmussen MM, Reimer KA, Kloner RA, Jennings RB. Infarct size reduction by propranolol before and after coronary ligation in dogs. Circulation. 1977; 56: 794-798.
17. Jardine DL, Charles CJ, Ashton RK, et al. Increased cardiac sympathetic nerve activity following acute myocardial infarction in a sheep model. J Physiol. 2005; 565 (Pt 1): 325-333.
18. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353: 2001-2007.
19. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353: 9-13.
20. Kalra PR, Morley C, Barnes S, et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013; 167: 2695-2699.